FDA Approves Sunharbo to Reduce Stroke Risk After Recent Mini-Stroke or Clot Event
On November 9, 2026, the U.S. Food and Drug Administration approved Sunharbo (asundexian) 50 mg tablets. The drug is the first factor XIa inhibitor cleared for use alongside standard antiplatelet therapy. It is intended for adults who recently suffered a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk mini-stroke, known as a transient ischemic attack. In a clinical study of 12,327 adults, taking Sunharbo once daily reduced the risk of a subsequent ischemic stroke by 26 percent compared to a placebo over a median 14.2 months of treatment. The approval offers a new option for patients who remain at risk for repeated strokes following an initial event. FDA granted the medication Fast Track and Priority Review designations before approving the drug, which Bayer HealthCare Pharmaceuticals Inc. will produce.
What was announced
The U.S. Food and Drug Administration approved Sunharbo 50 mg tablets on November 9, 2026. Made by Bayer HealthCare Pharmaceuticals Inc., it is the first factor XIa inhibitor approved to lower stroke risk when taken with antiplatelet therapy. The treatment is for adults who had a recent high-risk transient ischemic attack or a mild-to-moderate non-cardioembolic ischemic stroke, which is a stroke caused by a blood clot outside the heart.
In a study called OCEANIC-STROKE involving 12,327 adults, patients received either Sunharbo or a placebo within 72 hours of symptom onset. Both groups took antiplatelet therapy. Over a median treatment period of 14.2 months, taking Sunharbo once daily reduced the risk of ischemic stroke by 26 percent compared to placebo.
What it means
Patients who experience a stroke face a higher risk of having another one. Factor XIa inhibitors work as a new class of medication aimed at reducing clot risks when added to existing treatment regimens.
The FDA reported that overall rates of major bleeding were similar between Sunharbo and placebo groups. However, major bleeding was higher in patients over 75 years old and during the first 90 days of taking the drug. Gastrointestinal bleeding occurred more often with Sunharbo, and diarrhea was the most common adverse reaction, appearing in 3 percent or more of patients.
Doctors must manage specific restrictions. Sunharbo is not recommended for people with moderate or severe liver problems or those taking certain medications like carbamazepine. Patients must stop taking it at least 24 hours before elective surgery or invasive procedures. The drug is not approved for stroke risk reduction in people with atrial fibrillation.
What the announcement does not tell us
The FDA announcement does not state when Sunharbo will be available to patients or how much it will cost. It does not mention whether insurance plans or Medicare will cover the drug. The document also does not provide details on long-term outcomes beyond the study median follow-up period of 14.2 months.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.
FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
Opens www.fda.gov
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.